Sunshine Biopharma Inc. (SBFM) Stock Price

SBFMStock

$1.14−91.71%52W

Market Cap$4.42M

P/E—

PEG Ratio—

Div yield—

Beta-8.93

SBFM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-101.42%

Price vs S&P 500 (4W)-21.93%

VGM Score35.25

Book Value / Share (Quarterly)$43.86

P/TBV (Annual)0.29x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)102.91%

Cash Flow / Share (Quarterly)$-13.08

Price vs S&P 500 (YTD)-102.53%

Gross Margin (TTM)32.98%

Net Profit Margin (TTM)-17.02%

EPS (TTM)$-9.28

10-Day Avg Trading Volume0.19M

EPS Excl Extra (TTM)$-9.28

Revenue Growth (5Y)248.13%

EPS (Annual)$-14.37

ROI (Annual)-25.94%

Gross Margin (Annual)33.76%

Net Profit Margin (5Y Avg)-1223.93%

Cash / Share (Quarterly)$14.09

Revenue Growth QoQ (YoY)-9.13%

ROA (Last FY)-19.87%

Revenue Growth TTM (YoY)-2.05%

EBITD / Share (TTM)$-4.04

ROE (5Y Avg)-1211.75%

Operating Margin (TTM)-17.83%

Cash Flow / Share (Annual)$-12.57

P/B Ratio0.13x

P/B Ratio (Quarterly)0.24x

Net Income / Employee (Annual)$-119,500

EV / Revenue (TTM)-0.11x

Net Interest Coverage (TTM)-37.74x

ROA (TTM)-19.89%

EPS Incl Extra (Annual)$-14.37

Current Ratio (Annual)4.17x

Quick Ratio (Quarterly)1.87x

3-Month Avg Trading Volume1.33M

52-Week Price Return-91.71%

Revenue / Employee (TTM)$709,900

Tangible BV / Share (Quarterly)$39.95

P/S Ratio (Annual)0.08x

Asset Turnover (Annual)1.21x

52-Week High$24.30

Operating Margin (5Y Avg)-1197.75%

EPS Excl Extra (Annual)$-14.37

CapEx CAGR (5Y)270.37%

26-Week Price Return-90.17%

Quick Ratio (Annual)1.95x

13-Week Price Return-77.52%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.22x

Enterprise Value$-4.06M

Revenue / Share Growth (5Y)65.19%

Asset Turnover (TTM)1.17x

Revenue / Employee (Annual)$726,100

Inventory Turnover (Annual)1.94x

Pretax Margin (Annual)-16.40%

Cash / Share (Annual)$18.60

3-Month Return Std Dev127.64%

Gross Margin (5Y Avg)37.34%

Net Income / Employee (TTM)$-120,800

ROE (Last FY)-25.94%

Net Interest Coverage (Annual)-8.18x

EPS Basic Excl Extra (Annual)$-14.37

Receivables Turnover (TTM)9.52x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-9.28

Receivables Turnover (Annual)9.91x

ROI (TTM)-25.58%

P/S Ratio (TTM)0.08x

Pretax Margin (5Y Avg)-1222.65%

Revenue / Share (Annual)$87.33

Tangible BV / Share (Annual)$43.11

Price vs S&P 500 (52W)-110.02%

Year-to-Date Return-90.57%

5-Day Price Return3.57%

EPS Normalized (Annual)$-14.37

ROA (5Y Avg)-141.82%

Net Profit Margin (Annual)-16.46%

Month-to-Date Return-0.85%

Cash Flow / Share (TTM)$-1.09

EBITD / Share (Annual)$-14.18

Operating Margin (Annual)-17.15%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-156.30%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-9.28

P/TBV (Quarterly)0.26x

P/B Ratio (Annual)0.26x

Inventory Turnover (TTM)1.90x

Pretax Margin (TTM)-16.84%

Book Value / Share (Annual)$46.96

Price vs S&P 500 (13W)-80.31%

Beta-8.93x

Revenue / Share (TTM)$72.35

ROE (TTM)-25.58%

52-Week Low$1.03

gGradeC

mGradeF

vgmGradeD

SBFM Earnings Surprise History

Q2 25-3.90est. -1.10

Q3 25-1.90est. -1.30

Q4 25-4.60est. -2.70

Q1 26-2.50est. -1.60

Q2 26-1.15est. -1.20

SBFM Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
SBFMSunshine Biopharma Inc.	—	C	F	$1.14
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Sunshine Biopharma Inc.

Sunshine Biopharma Inc is a pharmaceutical company operating across oncology and antiviral therapeutics, with a commercial portfolio of generic prescription drugs in Canada and over-the-counter supplements. The company is developing a proprietary pipeline including K1.1, an mRNA therapeutic targeting liver cancer, and SBFM-PL4, a protease inhibitor candidate for SARS coronavirus infections.